UNBS5162 inhibits SKOV3 ovarian cancer cell proliferation by regulating the PI3K/AKT signalling pathway

Wang,Qiang; Shi,Wei

doi:10.3892/ol.2019.9890

UNBS5162 inhibits SKOV3 ovarian cancer cell proliferation by regulating the PI3K/AKT signalling pathway

Authors:
- Qiang Wang
- Wei Shi
View Affiliations

Affiliations: Department of Gynecology and Obstetrics, The Second Hospital of Jilin University, Changchun, Jilin 130000, P.R. China, Department of Gynecology and Obstetrics, Jinan Central Hospital Affiliated to Shandong University, Jinan, Shandong 250013, P.R. China
Published online on: January 4, 2019 https://doi.org/10.3892/ol.2019.9890
Pages: 2976-2982

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ovarian cancer is the gynaecological malignancy with the highest mortality rate worldwide, and effective and safe therapeutic methods are limited. UNBS5162, a derivative of naphthalimide, has a clear inhibitory effect on the proliferation of various tumour cells in vitro and in vivo as a pan‑antagonist of CXC chemokine ligand expression, but whether it serves a function in ovarian cancer remains unclear. The aim of the present study was to determine the effects of UNBS5162 on the proliferation, migration and invasion of ovarian cancer cells. The cell viability was detected using a Cell Counting Kit‑8 (CCK‑8) assay. The invasion and migration of SKOV3 cells were determined using Transwell assays. Cell apoptosis was determined using flow cytometry. The apoptosis‑associated proteins and associated factors, such as phosphoinositide 3‑kinase (PI3K)/protein kinase B (AKT) signalling pathway members, were detected using western blot analysis. The CCK‑8 assay revealed that SKOV3 cell viability was affected by UNBS5162 in a dose‑ and time‑dependent manner. In Transwell assays, UNBS5162 inhibited cell invasion and migration. Furthermore, it was identified that UNBS5162 markedly increased the apoptosis rate of SKOV3 cells. Simultaneously, the expression of the anti‑apoptotic protein B‑cell lymphoma 2 (Bcl‑2) was decreased and the expression of the pro‑apoptotic proteins active caspase‑3 and Bcl‑2‑associated X protein were increased in SKOV3 cells treated with UNBS5162. In addition, the expression levels of phospho (p‑)AKT/total AKT, p‑mammalian target of rapamycin (mTOR)/total mTOR, p‑p70 S6 kinase (p70S6K)/total p70S6K and cyclin D1 were decreased in the UNBS5162‑treated group. The results of the present study indicated that UNBS5162 inhibits proliferation, migration and invasion, and induces apoptosis in ovarian cancer cells, which may be regulated by the PI3K/AKT signalling pathway. These results suggest that UNBS5162 may be a potential novel drug for clinical ovarian cancer treatment.

View Figures

View References

1	Worzfeld T, Pogge von Strandmann E, Huber M, Adhikary T, Wagner U, Reinartz S and Müller R: The unique molecular and cellular microenvironment of ovarian cancer. Front Oncol. 7:242017. View Article : Google Scholar : PubMed/NCBI
2	Yan B, Yin F, Wang QI, Zhang W and Li LI: Integration and bioinformatics analysis of DNA-methylated genes associated with drug resistance in ovarian cancer. Oncol Lett. 12:157–166. 2016. View Article : Google Scholar : PubMed/NCBI
3	Faber MT, Kjaer SK, Dehlendorff C, Chang-Claude J, Andersen KK, Høgdall E, Webb PM, Jordan SJ; Australian Cancer Study (Ovarian Cancer); Australian Ovarian Cancer Study Group, ; et al: Cigarette smoking and risk of ovarian cancer: A pooled analysis of 21 case-control studies. Cancer Causes Control. 24:989–1004. 2013. View Article : Google Scholar : PubMed/NCBI
4	Weidle UH, Birzele F, Kollmorgen G and Rueger R: Mechanisms and targets involved in dissemination of ovarian cancer. Cancer Genomics Proteomics. 13:407–423. 2016. View Article : Google Scholar : PubMed/NCBI
5	Correa RJ, Valdes YR, Peart TM, Fazio EN, Bertrand M, McGee J, Préfontaine M, Sugimoto A, DiMattia GE and Shepherd TG: Combination of AKT inhibition with autophagy blockade effectively reduces ascites-derived ovarian cancer cell viability. Carcinogenesis. 35:1951–1961. 2014. View Article : Google Scholar : PubMed/NCBI
6	Li S, Xu S, Tang Y, Ding S, Zhang J, Wang S, Zhou G, Zhou C and Li X: Synthesis, anticancer activity and DNA-binding properties of novel 4-pyrazolyl-1,8-naphthalimide derivatives. Bioorg Med Chem Lett. 24:586–590. 2014. View Article : Google Scholar : PubMed/NCBI
7	Zhao L, Li J, Li Y, Liu J, Wirth T and Li Z: Selenium-containing naphthalimides as anticancer agents: Design, synthesis and bioactivity. Bioorg Med Chem. 20:2558–2563. 2012. View Article : Google Scholar : PubMed/NCBI
8	Ingrassia L, Lefranc F, Kiss R and Mijatovic T: Naphthalimides and azonafides as promising anti-cancer agents. Curr Med Chem. 16:1192–1213. 2009. View Article : Google Scholar : PubMed/NCBI
9	Dumont P, Ribaucour F, Quaquebeke EV, Darro F and Kiss R: UNBS3157, a new amonafide derivative with improved in vivo efficacy and decreased toxicity. Cancer Res. 66 Supp:11052006.PubMed/NCBI
10	Van Quaquebeke E, Mahieu T, Dumont P, Dewelle J, Ribaucour F, Simon G, Sauvage S, Gaussin JF, Tuti J, El Yazidi M, et al: 2,2,2-Trichloro-N-({2-[2-(dimethylamino)ethyl]-1,3-dioxo-2,3- dihydro-1H-benzo[de]isoquinolin-5-yl}carbamoyl)acetamide (UNBS3157), a novel nonhematotoxic naphthalimide derivative with potent antitumor activity. J Med Chem. 50:4122–4134. 2007. View Article : Google Scholar : PubMed/NCBI
11	Liu C, Xing J and Gao Y: UNBS5162 inhibits the proliferation of human A549 non-small-cell lung cancer cells by promoting apoptosis. Thorac Cancer. 9:105–111. 2018. View Article : Google Scholar : PubMed/NCBI
12	He D and Zhang S: UNBS5162 inhibits the proliferation of esophageal cancer squamous cells via the PI3K/AKT signalling pathway. Mol Med Rep. 17:549–555. 2018.PubMed/NCBI
13	Wang B, Shen J and Wang J: UNBS5162 inhibits proliferation of human retinoblastoma cells by promoting cell apoptosis. Onco Targets Ther. 10:5303–5309. 2017. View Article : Google Scholar : PubMed/NCBI
14	Mijatovic T, Mahieu T, Bruyere C, De Nève N, Dewelle J, Simon G, Dehoux MJ, van der Aar E, Haibe-Kains B, Bontempi G, et al: UNBS5162, a novel naphthalimide that decreases CXCL chemokine expression in experimental prostate cancers. Neoplasia. 10:573–586. 2008. View Article : Google Scholar : PubMed/NCBI
15	Agudelo D, Bourassa P, Bérubé G and Tajmir-Riahi HA: Intercalation of antitumor drug doxorubicin and its analogue by DNA duplex: Structural features and biological implications. Int J Biol Macromol. 66:144–150. 2014. View Article : Google Scholar : PubMed/NCBI
16	Gellerman G: Recent developments in the synthesis and applications of anticancer amonafide derivatives. A mini review. Letters Drug Design Discov. 13:47–63. 2016. View Article : Google Scholar
17	Zhao J, Lu M, Lai H, Lu H, Lalevée J, Barner-Kowollik C, Stenzel MH and Xiao P: Delivery of amonafide from fructose-coated nanodiamonds by oxime ligation for treatment of human breast cancer. Biomacromolecules. 19:481–489. 2018. View Article : Google Scholar : PubMed/NCBI
18	Ge C, Chang L, Zhao Y, Chang C, Xu X, He H, Wang Y, Dai F, Xie S and Wang C: Design, synthesis and evaluation of naphthalimide derivatives as potential anticancer agents for hepatocellular carcinoma. Molecules. 22:E3422017. View Article : Google Scholar : PubMed/NCBI
19	Mahieu T, Mijatovic T, Quaquebeke EV, Lefranc F, Vynckt FV, Darro F and Kiss R: UNBS5162 is a novel naphthalimide derivative that induces autophagy and senescence in human prostate cancer cells. Mol Cancer Ther. 6:3373S2007.
20	Antonini I, Volpini R, Dal Ben D, Lambertucci C and Cristalli G: Design, synthesis, and biological evaluation of new mitonafide derivatives as potential antitumor drugs. Bioorg Med Chem. 16:8440–8446. 2008. View Article : Google Scholar : PubMed/NCBI
21	Mahadevan D, Northfelt DW, Chalasani P, Rensvold D, Kurtin S, Von Hoff DD, Borad MJ and Tibes R: Phase I trial of UNBS5162, a novel naphthalimide in patients with advanced solid tumors or lymphoma. Int J Clin Oncol. 18:934–941. 2013. View Article : Google Scholar : PubMed/NCBI
22	Mei JM and Niu CS: Effects of CDNF on 6-OHDA-induced apoptosis in PC12 cells via modulation of Bcl-2/Bax and caspase-3 activation. Neurol Sci. 35:1275–1280. 2014. View Article : Google Scholar : PubMed/NCBI
23	Zhuang RJ, Ma J, Shi X, Ju F, Ma SP, Wang L, Cheng BF, Ma YW, Wang M, Li T, et al: Cold-inducible protein RBM3 protects UV irradiation-induced apoptosis in neuroblastoma cells by affecting p38 and JNK pathways and Bcl2 family proteins. J Mol Neurosci. 63:142–151. 2017. View Article : Google Scholar : PubMed/NCBI
24	Nakamura Y, Ise K, Yamazaki Y, Fujishima F, McNamara KM and Sasano H: Serotonin receptor 4 (5-hydroxytryptamine receptor Type 4) regulates expression of estrogen receptor beta and cell migration in hormone-naive prostate cancer. Indian J Pathol Microbiol. 60:33–37. 2017.PubMed/NCBI
25	Jordan VC: The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer. Endocr Relat Cancer. 22:R1–R31. 2015. View Article : Google Scholar : PubMed/NCBI
26	Shukla S, Fu P and Gupta S: Apigenin induces apoptosis by targeting inhibitor of apoptosis proteins and Ku70-Bax interaction in prostate cancer. Apoptosis. 19:883–894. 2014. View Article : Google Scholar : PubMed/NCBI
27	Zhou ZW, Li XX, He ZX, Pan ST, Yang Y, Zhang X, Chow K, Yang T, Qiu JX, Zhou Q, et al: Induction of apoptosis and autophagy via sirtuin1- and PI3K/Akt/mTOR-mediated pathways by plumbagin in human prostate cancer cells. Drug Des Devel Ther. 9:1511–1554. 2015. View Article : Google Scholar : PubMed/NCBI
28	Akinleye A, Avvaru P, Furqan M, Song Y and Liu D: Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. J Hematol Oncol. 6:882013. View Article : Google Scholar : PubMed/NCBI
29	Fang WL, Huang KH, Lan YT, Lin CH, Chang SC, Chen MH, Chao Y, Lin WC, Lo SS, Li AF, et al: Mutations in PI3K/AKT pathway genes and amplifications of PIK3CA are associated with patterns of recurrence in gastric cancers. Oncotarget. 7:6201–6220. 2016. View Article : Google Scholar : PubMed/NCBI
30	Huang J, Zhang L, Greshock J, Colligon TA, Wang Y, Ward R, Katsaros D, Lassus H, Butzow R, Godwin AK, et al: Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome. Genes Chromosomes Cancer. 50:606–618. 2011. View Article : Google Scholar : PubMed/NCBI
31	Zhang L, Huo X, Liao Y, Yang F, Gao L and Cao L: Zeylenone, a naturally occurring cyclohexene oxide, inhibits proliferation and induces apoptosis in cervical carcinoma cells via PI3K/AKT/mTOR and MAPK/ERK pathways. Sci Rep. 7:16692017. View Article : Google Scholar : PubMed/NCBI
32	Halacli SO and Dogan AL: FOXP1 regulation via the PI3K/Akt/p70S6K signalling pathway in breast cancer cells. Oncol Lett. 9:1482–1488. 2015. View Article : Google Scholar : PubMed/NCBI
33	Wang HY, Yang SL, Liang HF and Li CH: HBx protein promotes oval cell proliferation by up-regulation of cyclin D1 via activation of the MEK/ERK and PI3K/Akt pathways. Int J Mol Sci. 15:3507–3518. 2014. View Article : Google Scholar : PubMed/NCBI